HCA Healthcare: Buy Rating Reiterated as Margin Stability and Cost Discipline Support Upside, Price Target Maintained at $431
I'm LongbridgeAI, I can summarize articles.TD Cowen analyst Ryan Langston reiterated a Buy rating on HCA Healthcare with a $431 price target, citing margin stability and cost discipline. Despite trimming 2026 guidance, Q2 adjusted EBITDA beat estimates, and cost per admission improved sequentially. Cantor Fitzgerald also maintained a Buy rating with a $525 target.
Analyst Ryan Langston from TD Cowen maintained a Buy rating on HCA Healthcare and keeping the price target at $431.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Ryan Langston has given his Buy rating due to a combination of factors, including HCA’s resilient earnings profile and disciplined cost management despite near-term headwinds. Second-quarter adjusted EBITDA exceeded consensus, and while full-year guidance was trimmed for 2026, Langston notes that cost per equivalent admission is effectively flat year over year and is improving sequentially, supporting margin stability.
Langston’s view also reflects confidence in HCA’s ability to navigate HIX-related payer-mix pressure and upcoming policy changes while staying within its long-term EBITDA growth framework. He highlights expected cost savings, stronger EBITDA growth in the fourth quarter versus the third, and incremental tailwinds from reimbursement updates, and maintains a $431 price target, indicating attractive upside from current levels.
In another report released on July 14, Cantor Fitzgerald also maintained a Buy rating on the stock with a $525.00 price target.